Myron S. Czuczman
- Pathology and Forensic Medicine top 0.05%
- Lymphoma Diagnosis and Treatment 168
- Genetics top 0.1%
- Chronic Lymphocytic Leukemia Research 100
- Oncology top 0.5%
- CAR-T cell therapy research 44
- Viral-associated cancers and disorders 33
- Hematology top 0.5%
- Multiple Myeloma Research and Treatments 24
-
- Monoclonal and Polyclonal Antibodies Research 50
-
- Ubiquitin and proteasome pathways 21
-
- Lung Cancer Treatments and Mutations 15
- Co-authors
- Francisco J. Hernandez‐IlizaliturriLeo I. GordonAntonio J Grillo-LópezThomas E. WitzigChristos EmmanouilidesChristine A. WhiteNancy L. BartlettPratik S. Multani
- Journals
- Journal of Clinical Oncology (18 papers)Blood (113 papers)The Journal of Immunology (1 paper)
- Partner nations
- United StatesCanadaFrance
In The Last Decade
Myron S. Czuczman
235 papers receiving 10.2k citations
Hit Papers
Peers
Comparison fields: 5 of 120
- Pathology and Forensic Medicine 6.5k
- Genetics 3.5k
- Oncology 4.6k
- Hematology 1.3k
- Radiology, Nuclear Medicine and Imaging 2.5k
Countries citing papers authored by Myron S. Czuczman
This map shows the geographic impact of Myron S. Czuczman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Myron S. Czuczman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Myron S. Czuczman more than expected).
Fields of papers citing papers by Myron S. Czuczman
This network shows the impact of papers produced by Myron S. Czuczman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Myron S. Czuczman. The network helps show where Myron S. Czuczman may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Myron S. Czuczman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 92 | |
| 2 | 2014 | 44 | |
| 3 | 2014 | 143 | |
| 4 | 2014 | 27 | |
| 5 | 2013 | 32 | |
| 6 | 2013 | 119 | |
| 7 | 2013 | 45 | |
| 8 | 2012 | 123 | |
| 9 | 2012 | 51 | |
| 10 | 2010 | 255 | |
| 11 | 2010 | 6 | |
| 12 | 2010 | 66 | |
| 13 | Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activitybreakdown → | 2010 | 663 |
| 14 | 2009 | 371 | |
| 15 | 2008 | 90 | |
| 16 | 2007 | 93 | |
| 17 | 2007 | 29 | |
| 18 | 2006 | 314 | |
| 19 | Post-transcriptional regulation of Bax and Bak protein expression in rituximab and chemotherapy resistant B-cell non-Hodgkin’s lymphoma (NHL) cells | 2006 | 1 |
| 20 | 2002 | 6 |
About Myron S. Czuczman
Myron S. Czuczman is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology, having authored 241 papers that have together received 10.4k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (168 papers), Chronic Lymphocytic Leukemia Research (100 papers), Monoclonal and Polyclonal Antibodies Research (50 papers), CAR-T cell therapy research (44 papers), Viral-associated cancers and disorders (33 papers), Multiple Myeloma Research and Treatments (24 papers), Ubiquitin and proteasome pathways (21 papers) and Lung Cancer Treatments and Mutations (15 papers). The work is most often cited by research in Pathology and Forensic Medicine (6.5k citations), Genetics (3.5k citations) and Oncology (4.6k citations). Myron S. Czuczman has collaborated with scholars based in United States, Canada and France. Frequent co-authors include Francisco J. Hernandez‐Ilizaliturri, Leo I. Gordon, Antonio J Grillo-López, Thomas E. Witzig, Christos Emmanouilides, Christine A. White, Nancy L. Bartlett, Pratik S. Multani, Gregory A. Wiseman and Ann S. LaCasce. Their work appears in journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.